Viewpoint |

The Future of Gene Patents and the Implications for Medicine

Jacob S. Sherkow, JD1; Henry T. Greely, JD1
[+] Author Affiliations
1Center for Law and the Biosciences, Stanford University, Stanford, California
JAMA Intern Med. 2013;173(17):1569-1570. doi:10.1001/jamainternmed.2013.10153.
Text Size: A A A
Published online


On June 13, 2013, in Association for Molecular Pathology v Myriad Genetics Inc, the US Supreme Court unanimously ruled that naturally occurring genes cannot be patented. Synthetic transcripts of genes, however, can be patented.1 The case involved patent claims covering BRCA1 and BRCA2; mutations in these genes are linked to an increased risk for breast and ovarian cancer. Both sides quickly claimed victory. Harry Osterer, MD, a clinician and one of the plaintiffs, declared that the Court’s decision would help society “feel more of the impact of the genomics revolution.”2 The Biotechnology Industry Organization claimed that the decision left intact patents on the synthetic transcripts, “the commercially most important form of DNA used in biotechnology.”3 On the day the decision was announced, Myriad Genetics stock initially jumped 12% but finished down 6%. So what does this decision really mean, for both patent law and medicine?


genes ; patents

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 1

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
365 days: 2013 in review. Nature 2013;504(7480):344-9.